a research project to look at whether genomic newborn screening could be part of ontario’s standard screening program is just getting underway. the research is the first of its kind in north america.
the study will offer whole genome screening to 10,000 ontario newborns, using the same dried blood spot already collected for newborn screening, with consent.
the infant study, as it is called, will use non-commercial sequencing to look for pathogenic variants in 223 genes linked to serious, but treatable early-onset childhood diseases.
the disease the miller’s young daughter was diagnosed with, pku, was the start of universal newborn screening in ontario in 1965. at first, it was the only one babies were screened for, but the program has expanded from there.
today, the program run by cheo-based newborn screening ontario, established 20 years ago, screens newborns for more than 25 treatable conditions. those include metabolic diseases, endocrine diseases, sickle cell disease, cystic fibrosis and more.
every year, roughly 145,000 ontario babies are tested using blood taken from their heel 24 to 48 hours after birth. roughly 350 of those infants are identified with a treatable disease because of the screening. in 2024, the miller’s baby was among them.
dr. neal sondheimer, medical director of newborn screening ontario, calls pku the perfect example of why newborn screening is so important.
“the consequences of it can be almost entirely be avoided if you know it’s there and start treatment very early on in life,” he says. “to screen for something, you have to be able to do something about it that will make the child better. and, in general, the disease has to act in such a way that you wouldn’t know it was there if you didn’t do the screen.”
children with pku do not appear any different than children without pku at one week of age, he said. but, if you don’t start treating them at that stage, they will develop severe cognitive impairment and that becomes irreversible.